Knockoff biotech drugs could be the next big thing in the phrama world.
Known as "biosimilars," these drugs are less expensive than their biotech cousins that have fueled a boom in the drug industry.
That's why Pfizer (PFE) shelled out $16 billion earlier this year to acquire Hospira (HSP), a global leader in the biosimilar business. The deal represented a solid 39% premium to Hospira's share price at the time.
Related: America's 10 fastest-growing companies
